Second unanimous FDA adcomm vote boosts bluebird bio
pharmaphorum
JUNE 12, 2022
Cases of cancer associated with insertional mutagenesis, caused when the viral vectors used to deliver the gene therapy to host cells, have been seen with bluebird’s gene therapies but have been more apparent in trials involving its CALD and sickle cell disease candidates than beti-cel.
Let's personalize your content